Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson’s disease and l-DOPA-induced dyskinesia (2020)
- Authors:
- USP affiliated authors: GUIMARÃES, FRANCISCO SILVEIRA - FMRP ; GUIMARAES, ELAINE APARECIDA DEL BEL BELLUZ - FORP ; FERREIRA JUNIOR, NILSON CARLOS - FMRP ; PEREIRA, MAURÍCIO DOS SANTOS - FORP
- Unidades: FMRP; FORP
- DOI: 10.1007/s12640-019-00109-8
- Subjects: RECEPTORES; CANABINOIDES; INFLAMAÇÃO; DOENÇA DE PARKINSON
- Keywords: Cannabinoid receptor; Cannabinoid system; Endocannabinoids; Neuroinflammation; Peroxisome proliferator-activated receptor; Transient receptor potential vanilloid receptor
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Neurotoxicity Research
- ISSN: 1029-8428
- Volume/Número/Paginação/Ano: v. 37, n. 1, p. 12-29, 2020
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
FERREIRA JUNIOR, Nilson Carlos et al. Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson’s disease and l-DOPA-induced dyskinesia. Neurotoxicity Research, v. 37, n. 1, p. 12-29, 2020Tradução . . Disponível em: https://doi.org/10.1007/s12640-019-00109-8. Acesso em: 04 out. 2024. -
APA
Ferreira Junior, N. C., Pereira, M. dos S., Guimarães, F. S., & Del Bel, E. A. (2020). Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson’s disease and l-DOPA-induced dyskinesia. Neurotoxicity Research, 37( 1), 12-29. doi:10.1007/s12640-019-00109-8 -
NLM
Ferreira Junior NC, Pereira M dos S, Guimarães FS, Del Bel EA. Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson’s disease and l-DOPA-induced dyskinesia [Internet]. Neurotoxicity Research. 2020 ; 37( 1): 12-29.[citado 2024 out. 04 ] Available from: https://doi.org/10.1007/s12640-019-00109-8 -
Vancouver
Ferreira Junior NC, Pereira M dos S, Guimarães FS, Del Bel EA. Cannabidiol and cannabinoid compounds as potential strategies for treating Parkinson’s disease and l-DOPA-induced dyskinesia [Internet]. Neurotoxicity Research. 2020 ; 37( 1): 12-29.[citado 2024 out. 04 ] Available from: https://doi.org/10.1007/s12640-019-00109-8 - Cannabidiol prevents LPS-induced microglial inflammation by inhibiting ROS/NF-κB-dependent signaling and glucose consumption
- Rifampicin and its derivative Rifampicin quinone reduce microglial inflammatory responses and neurodegeneration induced in vitro by α-Synuclein fibrillary aggregates
- The chemically-modified tetracycline COL-3 and its parent compound doxycycline prevent microglial inflammatory responses by reducing glucose-mediated oxidative stress
- CMT-3 targets different α-synuclein aggregates mitigating their toxic and inflammogenic effects
- Contributive role of TNF-α to L-DOPA-induced dyskinesia in a unilateral 6-OHDA lesion model of parkinson’s disease
- Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats
- Attenuation of restraint stress-induced c-jun mrna expresion in the hippocampus by midazolam and n-methyl-d-aspartate (nmd)antagonist
- Midazolam and the n-methyl-d-aspartate (mmda) receptor antagonist apz attenuate stress -induced expression of c-fos mrna in the dentate gyrus
- Efeito ansiogenico do l- noarg , um inibidor da formacao do oxido nitrico
- Expressão da proteína fós no cérebro de ratos após estímulo térmico nocivo: evidências da participação do núcleo pré-tectal anterior (NPA) na nocicepção
Informações sobre o DOI: 10.1007/s12640-019-00109-8 (Fonte: oaDOI API)
Download do texto completo
| Tipo | Nome | Link | |
|---|---|---|---|
 | 003012089.pdf |
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
